For a patient with heart failure who cannot afford empagliflozin (Jardiance) or sacubitril/valsartan (Entresto) and is currently taking amlodipine, what alternative medication options are recommended?

Alternative Options for Heart Failure When Jardiance and Entresto Are Unaffordable

For a patient with heart failure who cannot afford empagliflozin (Jardiance) or sacubitril/valsartan (Entresto), the best alternative is to initiate or optimize generic ACE inhibitors (such as lisinopril or enalapril) or generic ARBs (such as losartan or valsartan), combined with a beta-blocker (carvedilol or metoprolol succinate) and a mineralocorticoid receptor antagonist (spironolactone), all of which are available as low-cost generics and provide high-value, mortality-reducing therapy. 1

Core Guideline-Directed Medical Therapy (GDMT) Algorithm

The 2022 AHA/ACC/HFSA guidelines establish a clear hierarchy for heart failure with reduced ejection fraction (HFrEF) treatment 1:

First-Line Affordable Alternatives:

1. ACE Inhibitors (First Choice if not on ARNi):

• Lisinopril: Start 2.5-5 mg once daily, target 20-40 mg daily
• Enalapril: Start 2.5 mg twice daily, target 10-20 mg twice daily
• Ramipril: Start 1.25-2.5 mg once daily, target 10 mg daily

These medications reduce all-cause mortality by 17% with a number needed to treat (NNT) of 26 over 36 months 1. ACE inhibitors are consistently high-value therapy even with generic pricing 1.

2. If ACE Inhibitor Intolerant (cough or angioedema):

• Losartan: Start 25-50 mg once daily, target 50-150 mg daily
• Valsartan: Start 20-40 mg once daily, target 160 mg twice daily
• Candesartan: Start 4-8 mg once daily, target 32 mg daily

ARBs provide similar mortality benefit to ACE inhibitors and are also high-value with generic availability 1.

3. Beta-Blockers (Essential - DO NOT Skip):

• Carvedilol: Start 3.125 mg twice daily, target 25-50 mg twice daily
• Metoprolol succinate: Start 12.5-25 mg once daily, target 200 mg daily

Beta-blockers provide the most robust mortality reduction (34% relative risk reduction, NNT of 9 over 36 months) 1. This is the single most cost-effective intervention in heart failure.

4. Mineralocorticoid Receptor Antagonists:

• Spironolactone: Start 12.5-25 mg once daily, target 25-50 mg daily

Provides 30% mortality reduction and is available as an inexpensive generic 1.

Critical Consideration About Amlodipine

Important caveat: Amlodipine is a calcium channel blocker that does NOT reduce mortality in heart failure and may worsen outcomes in some patients 1. While it can be continued for blood pressure control if needed, it should never substitute for GDMT. The patient needs ACE inhibitor/ARB + beta-blocker + MRA as the foundation, regardless of amlodipine use.

Practical Titration Strategy

The guidelines emphasize titrating to target doses shown effective in trials, even if symptoms improve at lower doses 1:

1. Start all three medication classes (ACE/ARB, beta-blocker, MRA) at low doses
2. Uptitrate every 1-2 weeks based on blood pressure, heart rate, potassium, and creatinine
3. Aim for target doses from clinical trials, not just symptom improvement
4. Monitor potassium (keep <5.0 mEq/L) and creatinine closely when combining ACE/ARB with MRA

Cost-Saving Resources

When even generics are challenging 2:

• Medicare Extra Help/Low-Income Subsidy: For those earning <$17,226 annually, generic copays are capped at $3.60, making annual GDMT costs under $50
• Discount programs: GoodRx, CostPlus, SingleCare can reduce generic medication costs further
• Financial navigation services: Social workers or financial counselors can help identify assistance programs

Why This Approach Works

The 2022 guidelines explicitly state: "If the benefit from ARNi is not feasible, treatment with an ACEi or ARB provides high economic value" 2. The combination of generic ACE inhibitor/ARB + beta-blocker + MRA provides:

• Proven mortality reduction (each class independently reduces death)
• Annual costs potentially under $200-300 for all three medications
• Equivalent foundational benefit to more expensive regimens
• Enables later addition of SGLT2i or ARNi if financial situation improves

What About SGLT2 Inhibitors as Jardiance Alternative?

While empagliflozin (Jardiance) and dapagliflozin are both SGLT2 inhibitors with proven benefit 1, neither has a generic equivalent yet. If cost is prohibitive for Jardiance, the other SGLT2i will likely be similarly unaffordable. Focus on optimizing the three affordable generic medication classes first - this provides substantial mortality benefit before considering SGLT2i.

Bottom Line Algorithm

1. Verify heart failure type (reduced vs. preserved ejection fraction) - this answer assumes HFrEF
2. Start generic ACE inhibitor (lisinopril 2.5-5 mg daily) OR ARB if ACE-intolerant
3. Start generic beta-blocker (carvedilol 3.125 mg twice daily)
4. Start spironolactone (12.5-25 mg daily) if potassium <5.0 and creatinine acceptable
5. Uptitrate every 1-2 weeks to target doses
6. Continue amlodipine only if needed for additional blood pressure control
7. Reassess financial situation periodically for potential addition of SGLT2i or ARNi when affordable

This approach prioritizes mortality reduction and quality of life using evidence-based, affordable medications that form the backbone of heart failure therapy.